Bayer's Aliqopa Approval Gives PI3K Class A Second Chance in Follicular Lymphoma

14 Sep 2017

• By Emily Hayes

Bayer's PI3 kinase inhibitor copanlisib now has accelerated approval in a common type of non-Hodgkin lymphoma, but the drug's competitive profile still awaits Phase III data.

White blood cells in peripheral blood smear, Wright stain

Bayer's Aliqopa Approval Gives PI3K Class A Second Chance in Follicular Lymphoma

More from Anticancer

More from Therapy Areas